A 2009 Update on the Treatment of Patients with Hormone Receptor—Positive Breast Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Anderson, 2002, Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database, Breast Cancer Res Treat, 76, 27, 10.1023/A:1020299707510
Harvey, 1999, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J Clin Oncol, 17, 1474, 10.1200/JCO.1999.17.5.1474
Love, 2002, Oophorectomy for breast cancer: history revisited, J Natl Cancer Inst, 94, 1433, 10.1093/jnci/94.19.1433
Kuiper, 1996, Cloning of a novel estrogen receptor expressed in rat prostate and ovary, Proc Natl Acad Sci U S A, 93, 5925, 10.1073/pnas.93.12.5925
Osborne, 2001, Estrogen receptor: current understanding of its activation and modulation, Clin Cancer Res, 7, 4338s
Palmieri, 2002, Estrogen receptor beta in breast cancer, Endocr Relat Cancer, 9, 1, 10.1677/erc.0.0090001
Björnström, 2005, Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes, Mol Endocrinol, 19, 833, 10.1210/me.2004-0486
Nicholson, 1999, Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer, Endocr Relat Cancer, 6, 373, 10.1677/erc.0.0060373
Font de Mora, 2000, AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor, Mol Cell Biol, 20, 5041, 10.1128/MCB.20.14.5041-5047.2000
Shou, 2004, Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2–positive breast cancer, J Natl Cancer Inst, 96, 926, 10.1093/jnci/djh166
Ellis, 2001, Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1–and/or ErbB-2–positive, estrogen receptor–positive primary breast cancer: evidence from a phase III randomized trial, J Clin Oncol, 19, 3808, 10.1200/JCO.2001.19.18.3808
Sørlie, 2003, Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci U S A, 100, 8418, 10.1073/pnas.0932692100
Bardou, 2003, Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases, J Clin Oncol, 21, 1973, 10.1200/JCO.2003.09.099
Dowsett, 2005, Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists, J Clin Oncol, 23, 2477, 10.1200/JCO.2005.07.559
Coates, 2007, Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98, J Clin Oncol, 25, 486, 10.1200/JCO.2006.08.8617
Arimidex, Tamoxifen, Alone or in Combination (ATAC) trialists' group, 2008, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial, Lancet Oncol, 9, 45, 10.1016/S1470-2045(07)70385-6
Smith, 2005, Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial, J Clin Oncol, 23, 5108, 10.1200/JCO.2005.04.005
Kapp, 2006, Discovery and validation of breast cancer subtypes [published correction appears in BMC Genomics 2007; 8:101], BMC Genomics, 7, 231, 10.1186/1471-2164-7-231
2005, A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer [published correction appears in N Engl J Med 2006; 354:2200], N Engl J Med, 353, 2747, 10.1056/NEJMoa052258
Brinton, 2008, Recent trends in breast cancer among younger women in the United States, J Natl Cancer Inst, 100, 1643, 10.1093/jnci/djn344
2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0
Albain K, Barlow W, O'Malley F, et al. Concurrent ICAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III Intergroup trial 0100 (SWOG-8814). Paper presented at: The 27th Annual San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio, TX. Abstract 37.
Peto R, Davies C. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11500 women—preliminary results. Paper presented at: The 30th Annual San Antonio Breast Cancer Symposium; December 13-17, 2007; San Antonio, TX. Abstract 48.
Gray, 2008, aTTom (Adjuvant Tamoxifen—To Offer More?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—preliminary results, J Clin Oncol, 26, 10s
Klijn, 2001, Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials, J Clin Oncol, 19, 343, 10.1200/JCO.2001.19.2.343
Roché, 2006, Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial, Ann Oncol, 17, 1221, 10.1093/annonc/mdl107
Price, 2005, Clinical trial update: International Breast Cancer Study Group, Breast Cancer Res, 7, 252, 10.1186/bcr1334
Forward, 2004, Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer, Br J Cancer, 90, 590, 10.1038/sj.bjc.6601557
Gnant, 2009, Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N Engl J Med, 360, 679, 10.1056/NEJMoa0806285
Mouridsen, 2003, Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group, J Clin Oncol, 21, 2101, 10.1200/JCO.2003.04.194
Goss, 2005, Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17, J Natl Cancer Inst, 97, 1262, 10.1093/jnci/dji250
Dowsett, 2008, Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial, J Clin Oncol, 26, 1059, 10.1200/JCO.2007.12.9437
Coombes, 2007, Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial [published correction appears in Lancet 2007; 369:906], Lancet, 369, 559, 10.1016/S0140-6736(07)60200-1
Jakesz, 2005, Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial, Lancet, 366, 455, 10.1016/S0140-6736(05)67059-6
Jonat, 2006, Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive earlystage breast cancer: a meta-analysis [published correction appears in Lancet Oncol 2007; 8:6], Lancet Oncol, 7, 991, 10.1016/S1470-2045(06)70948-2
Mouridsen, 2008, BIG 1-98: a randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer, Breast Cancer Res Treat, 69, 66s
Jones, 2008, Results of the first planned analysis of the TEAM (Tamoxifen Exemestane Adjuvant Multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer, Breast Cancer Res Treat, 69, 67s
Ingle, 2008, Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies, Breast Cancer Res Treat, 69, 66s
Jakesz, 2005, Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group trial 6a (ABCSG-6a), J Clin Oncol, 23, 10s
Mamounas, 2008, Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial, J Clin Oncol, 26, 1965, 10.1200/JCO.2007.14.0228
Paik, 2004, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, 351, 2817, 10.1056/NEJMoa041588
Paik, 2006, Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor–positive breast cancer, J Clin Oncol, 24, 3726, 10.1200/JCO.2005.04.7985
Albain K, Barlow W, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100). Paper presented at: The 30th Annual San Antonio Breast Cancer Symposium; December 13-17, 2007; San Antonio, TX. Abstract 10.
Wan, 2001, Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California, Pharmacogenetics, 11, 489, 10.1097/00008571-200108000-00004
Sachse, 1998, Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine, Pharmacogenetics, 8, 181, 10.1097/00008571-199804000-00010
Nakamura, 1985, Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations, Clin Pharmacol Ther, 38, 402, 10.1038/clpt.1985.194
Stearns, 2008, Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?, Expert Rev Mol Med, 10, e34, 10.1017/S1462399408000896
Goetz, 2009, Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial, Cancer Res, 69, 76s, 10.1158/0008-5472.SABCS-57
Dunning, 2004, Polymorphisms associated with cir-culating sex hormone levels in postmenopausal women, J Natl Cancer Inst, 96, 936, 10.1093/jnci/djh167
Haiman, 2007, Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women, Cancer Res, 67, 1893, 10.1158/0008-5472.CAN-06-4123
Sowers, 2006, Aromatase gene (CYP 19) polymorphisms and endogenous androgen concentrations in a multiracial/multiethnic, multisite study of women at midlife, Am J Med, 119, S23, 10.1016/j.amjmed.2006.07.003
Colomer, 2008, A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma, Clin Cancer Res, 14, 811, 10.1158/1078-0432.CCR-07-1923
Fisher, 1997, Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18, J Clin Oncol, 15, 2483, 10.1200/JCO.1997.15.7.2483
van der Hage, 2001, Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902, J Clin Oncol, 19, 4224, 10.1200/JCO.2001.19.22.4224
Wolmark, 2001, Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18, J Natl Cancer Inst Monogr, 96, 10.1093/oxfordjournals.jncimonographs.a003469
Ellis, 2008, Outcome prediction for estrogen receptor–positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics, J Natl Cancer Inst, 100, 1380, 10.1093/jnci/djn309
Guarneri, 2006, Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors, J Clin Oncol, 24, 1037, 10.1200/JCO.2005.02.6914
Semiglazov, 2007, Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer [in Russian], Vopr Onkol, 53, 400
Fennessy, 2004, Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer, Br J Surg, 91, 699, 10.1002/bjs.4603
Hellman, 1991, Natural history of breast cancer, 165
Breast cancer
Broglio, 2008, Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer, J Clin Oncol, 26, 41s
MacFarlane, 2008, Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series, J Clin Oncol, 26, 41s
Bonneterre, 2001, Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma, Cancer, 92, 2247, 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y
Paridaens, 2008, Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group, J Clin Oncol, 26, 4883, 10.1200/JCO.2007.14.4659
Thürlimann, 2003, Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as firstline treatment for advanced breast cancer in postmenopausal women, Eur J Cancer, 39, 2310, 10.1016/S0959-8049(03)00602-6
Gennatas, 2006, Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole: a phase II trial conducted by the Hellenic Group of Oncology (HELGO), Tumori, 92, 13, 10.1177/030089160609200103
Chia, 2008, Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor–positive, advanced breast cancer: results from EFECT, J Clin Oncol, 26, 1664, 10.1200/JCO.2007.13.5822
Ellis, 2008, A comparison of high-dose (HD, 500 mg) fulvestrant vs anastrozole (1 mg) as first-line treatments for advanced breast cancer: results from FIRST, Breast Cancer Res Treat, 69, 397s
Ellis, 2008, A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer, Breast Cancer Res Treat, 69, 68s
Carlson, 2003, Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole, Breast Cancer Res Treat, 80, S19, 10.1023/A:1025459232293
Stanway, 2006, Phase I study of STX 64 (667 coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor, Clin Cancer Res, 12, 1585, 10.1158/1078-0432.CCR-05-1996
Ali, 2002, Endocrine-responsive breast cancer and strategies for combating resistance, Nat Rev Cancer, 2, 101, 10.1038/nrc721
Knowlden, 2003, Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells, Endocrinology, 144, 1032, 10.1210/en.2002-220620
Osborne, 2007, Randomized phase II study of gefitinib (Iressa) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer, Breast Cancer Res Treat, 106, S107
Cristofanilli, 2008, A phase II multicenter, double-blind, randomized trial to compare anastrozole plus [gefitinib] with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC), J Clin Oncol, 26, 44s
Smith, 2007, A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer, J Clin Oncol, 25, 3816, 10.1200/JCO.2006.09.6578
Mackey, 2006, Trastuzumab prolongs progressionfree survival in hormone-dependent and HER2-positive metastatic breast cancer, Breast Cancer Res Treat, 100, S5
Johnston, 2009, Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 trial, Cancer Res, 69, 74s, 10.1158/0008-5472.SABCS-46
Shaw, 2006, Ras, PI(3)K and mTOR signalling controls tumour cell growth, Nature, 441, 424, 10.1038/nature04869
deGraffenried, 2004, Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity, Clin Cancer Res, 10, 8059, 10.1158/1078-0432.CCR-04-0035
Rudolf, 2004, The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative FAD001 with the aromatase inhibitor letrozole in breast carcinomas, Proc Amer Assoc Cancer Res, 45
Baselga, 2008, Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer, J Clin Oncol, 26, 13s
Chow, 2006, Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer, Breast Cancer Res Treat, 100, S286
Johnston, 2008, A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy, Breast Cancer Res Treat, 110, 327, 10.1007/s10549-007-9726-1